Stockreport

Bristol-Myers Squibb Highlights Breadth of Immuno-Oncology–Based Combination Research and Commitment to Advancing Precision Medicine at ASCO 2018

Bristol-Myers Squibb Company  (BMY) 
Last bristol-myers squibb company earnings: 2/6 07:05 am Check Earnings Report
US:NYSE Investor Relations: bms.com/investors.html
PDF First analysis from Phase 3 CheckMate -227 Part 1b in first-line non-small cell lung cancer, assessing Opdivo plus chemotherapy and Opdivo plus Yervoy ve [Read more]